Specialty pharmaceuticals represent the fastest-growing segment of the pharmaceutical market, but they come with the most complex access barriers. Prior authorization requirements, step therapy mandates, and specialty pharmacy routing create administrative friction that delays patient starts and frustrates the physicians who prescribe them. In 2026, specialty pharma commercial teams are increasingly turning to virtual assistants to manage this friction at scale.
The Prior Authorization Bottleneck
Prior authorization denial rates for specialty drugs have climbed steadily over the past three years. According to the American Medical Association's 2025 Prior Authorization Survey, 94% of physicians reported that PA requirements delay patient access to necessary treatments, and 80% said PA processes have become more burdensome compared to five years ago.
For specialty pharma sales organizations, PA delays directly suppress prescription volume. When a physician writes a script for a high-cost specialty drug and it sits in a PA queue for two to three weeks, the prescriber may switch to an alternative, the patient may disengage, and the rep's call effort goes unrealized. Reducing PA friction is not just a patient access issue — it is a core commercial lever.
Virtual assistants trained in specialty pharmacy access workflows can support the PA process without crossing into clinical or billing territory. They can reach out to physician office staff to confirm PA submissions are complete, identify missing clinical documentation, connect offices with hub services and patient support programs, and track PA status across a panel of pending prescriptions. IQVIA data from 2025 estimates that proactive PA support reduces average time-to-therapy starts for specialty drugs by 6 to 12 days.
Physician Outreach at Scale
Specialty pharma reps typically carry smaller target lists than primary care counterparts — often 50 to 150 physicians — but each relationship requires more intensive management. Clinical complexity, formulary nuance, patient selection criteria, and payer access issues all require tailored communication. Maintaining consistent outreach cadence across a target panel while managing access restrictions is a persistent challenge.
Virtual assistants can extend the rep's outreach capacity without diluting the quality of physician-facing communication. A trained VA can manage email and phone outreach cadences for non-clinical touchpoints: meeting confirmation follow-ups, resource delivery (speaker program invitations, reprint requests, lunch coordination), post-call thank-you notes, and meeting prep packages for upcoming HCP visits.
Veeva Systems' 2025 Engage Benchmark Report found that specialty reps who supplemented direct HCP contact with coordinated non-personal outreach saw 31% higher physician engagement scores compared to reps relying solely on field calls. VAs executing the coordination layer of that outreach model free reps to focus on the high-value clinical conversations that require their expertise.
Connecting the Commercial and Access Ecosystems
One of the most valuable roles VAs play in specialty pharma is serving as a coordination layer between the sales organization and the access infrastructure — hub services, specialty pharmacies, patient assistance programs, and reimbursement support teams. These systems are designed to help patients start and stay on therapy, but they require consistent communication management that reps are rarely positioned to provide.
A VA can maintain regular contact with hub case managers to check on patient case status, alert reps when a case requires their intervention, and ensure that physician offices are connected to the right support resources at the right time. McKinsey's 2025 Patient Services Benchmarking Report found that specialty brands with active coordination between field sales and hub services achieved 14% higher 90-day adherence rates than those with siloed operations.
PhRMA member companies have increasingly cited integrated patient access support as a differentiating commercial capability — one that smaller specialty pharma organizations can approximate through well-trained VA support at a fraction of the cost of a dedicated access team.
Specialty pharma commercial teams building out PA support and physician outreach infrastructure should consider Stealth Agents for trained virtual assistants with life sciences and healthcare access experience.
Sources
- American Medical Association, 2025 Prior Authorization Survey, ama-assn.org
- Veeva Systems, 2025 Engage Benchmark Report, veeva.com
- McKinsey & Company, Patient Services Benchmarking Report 2025, mckinsey.com